Segall Bryant & Hamill LLC Sells 148,090 Shares of Aurinia Pharmaceuticals Inc (NASDAQ:AUPH)

Segall Bryant & Hamill LLC cut its stake in shares of Aurinia Pharmaceuticals Inc (NASDAQ:AUPH - Free Report) TSE: AUP by 28.7% in the 1st quarter, according to its most recent Form 13F filing with the SEC. The fund owned 368,787 shares of the biotechnology company's stock after selling 148,090 shares during the period. Segall Bryant & Hamill LLC owned 0.27% of Aurinia Pharmaceuticals worth $2,965,000 as of its most recent filing with the SEC.

Other hedge funds also recently made changes to their positions in the company. Invesco Ltd. increased its stake in shares of Aurinia Pharmaceuticals by 1.0% in the 4th quarter. Invesco Ltd. now owns 144,112 shares of the biotechnology company's stock valued at $1,294,000 after purchasing an additional 1,421 shares during the last quarter. GAMMA Investing LLC boosted its holdings in shares of Aurinia Pharmaceuticals by 56.1% during the 1st quarter. GAMMA Investing LLC now owns 4,852 shares of the biotechnology company's stock valued at $39,000 after acquiring an additional 1,744 shares in the last quarter. Bridgefront Capital LLC boosted its holdings in shares of Aurinia Pharmaceuticals by 12.9% during the 4th quarter. Bridgefront Capital LLC now owns 16,606 shares of the biotechnology company's stock valued at $149,000 after acquiring an additional 1,891 shares in the last quarter. Cetera Investment Advisers boosted its holdings in shares of Aurinia Pharmaceuticals by 3.2% during the 4th quarter. Cetera Investment Advisers now owns 64,638 shares of the biotechnology company's stock valued at $580,000 after acquiring an additional 2,000 shares in the last quarter. Finally, Teacher Retirement System of Texas boosted its holdings in shares of Aurinia Pharmaceuticals by 5.9% during the 4th quarter. Teacher Retirement System of Texas now owns 36,098 shares of the biotechnology company's stock valued at $324,000 after acquiring an additional 2,020 shares in the last quarter. 36.83% of the stock is owned by institutional investors and hedge funds.

Analyst Ratings Changes

Separately, Wall Street Zen raised Aurinia Pharmaceuticals from a "buy" rating to a "strong-buy" rating in a research report on Thursday, March 27th.

Aurinia Pharmaceuticals Price Performance

Shares of Aurinia Pharmaceuticals stock traded up $0.26 during trading on Tuesday, hitting $8.88. The stock had a trading volume of 1,254,245 shares, compared to its average volume of 1,404,591. The firm has a market cap of $1.20 billion, a price-to-earnings ratio of 31.71 and a beta of 1.16. Aurinia Pharmaceuticals Inc has a 12 month low of $5.20 and a 12 month high of $10.67. The business's 50-day moving average is $8.16 and its 200 day moving average is $8.06. The company has a current ratio of 5.93, a quick ratio of 5.26 and a debt-to-equity ratio of 0.16.

Aurinia Pharmaceuticals (NASDAQ:AUPH - Get Free Report) TSE: AUP last released its earnings results on Monday, May 12th. The biotechnology company reported $0.16 EPS for the quarter, beating analysts' consensus estimates of $0.08 by $0.08. The business had revenue of $62.47 million for the quarter, compared to analysts' expectations of $61.06 million. Aurinia Pharmaceuticals had a return on equity of 14.27% and a net margin of 16.11%. As a group, sell-side analysts anticipate that Aurinia Pharmaceuticals Inc will post 0.11 earnings per share for the current year.

Aurinia Pharmaceuticals Profile

Aurinia Pharmaceuticals Inc, a commercial-stage biopharmaceutical company, focuses on developing and commercializing therapies to treat various diseases with unmet medical need in the United States. It offers LUPKYNIS for the treatment of adult patients with active lupus nephritis. It has a collaboration and license agreement with Otsuka Pharmaceutical Co, Ltd.